STAT3 and glioblastoma: Notably, preclinical evidence has substantiated the therapeutic potential of STAT3 inhibition, either by RNAi knockdown or pharmacological inhibitors, for GBM treatment, thereby highlighting STAT3 as a promising target for developing novel GBM therapeutics [15,16].